Innova Captab Peer Comparison

NSE: INNOVACAP | BSE: 544067

₹1,055.10

₹33.55 (3.28%)

As on 28-Aug-2026IST

Market cap

₹6,036 Cr

Revenue (TTM)

₹1,749 Cr

P/E Ratio

38.6

P/B Ratio

5.3

Div. Yield

0.2 %

Edit

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	6,036	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	1,749	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	156.29	414.00	288.22	-371.81	387.35
Net Margin (%)	8.89	11.23	14.79	-3.93	26.01
RoE (%)	14.87	8.38	29.77	-3.85	25.18
Price to Earnings	38.62	78.49	103.71	--	69.57
Price-To-Book	5.32	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1,630.02	3,373.00	1,753.96	8,869.08	1,006.88
Total Income	1,648.73	3,510.00	1,762.66	9,111.51	1,023.80
Total Expenditure	1,398.39	2,747.00	1,354.69	7,976.59	774.80
EBITDA	231.63	626.00	399.26	892.49	232.07
Depreciation	45.18	227.00	45.26	831.24	26.62
EBIT	186.45	399.00	354.00	61.25	205.45
Interest	16.90	213.00	42.17	340.80	6.22
Other Income	18.71	137.00	8.70	242.43	16.93
Exceptional Items	--	-85.00	--	-196.14	--
Profit before Tax	188.26	238.00	320.53	-176.06	216.16
Provision for Tax	47.35	39.00	73.80	149.88	55.75
Profit after Tax	140.92	199.00	246.74	-325.94	160.42

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	1,090.79	4,940.00	1,288.82	8,162.62	1,309.63
Minority Interest	--	341.00	0.00	--	10.45
Non-Current Liabilities	250.59	1,235.00	189.02	4,529.41	26.93
Current Liabilities	516.68	1,622.00	835.87	4,874.74	202.25
Total Liabilities	1,858.06	8,578.00	2,326.71	17,723.32	1,549.26

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	913.00	5,441.00	631.90	10,258.66	757.63
Current Assets	945.06	2,606.00	1,681.81	7,308.11	791.64
Total Assets	1,858.06	8,578.00	2,326.71	17,723.32	1,549.26
Total Debt*	342.67	2,125.00	259.37	5,495.48	8.18
Net Current Assets	428.38	984.00	845.94	2,433.37	589.39
Contingent Liabilities	--	768.26	19.09	95.72	15.38

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	116.52	390.00	205.05	1,652.60	118.34
Cash Flow from Investing Activities	-107.12	-241.00	-409.72	-826.03	-223.94
Cash from Financing Activities	-21.72	-54.00	283.07	-38.98	261.12
Net Cash Inflow / Outflow	-12.32	95.00	78.39	787.59	155.52

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	15.04	6.79	29.22	1.24	20.14
ROE (%)	13.75	4.29	27.84	-4.04	16.19
ROA (%)	8.17	2.53	13.11	-1.98	12.13
EBIT Margin (%)	15.36	22.62	23.26	12.80	24.73
Net Margin (%)	8.55	5.67	14.00	-3.58	15.67
Cash Profit Margin (%)	11.22	10.98	7.71	4.80	18.58

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	31.06	11.99	36.57	-3.08	40.34
EBIT Growth (%)	26.31	67.69	52.29	-28.15	83.12
Net Profit Growth (%)	9.87	449.12	83.64	-457.66	229.35
EPS Growth (%)	9.87	553.20	71.44	-456.91	67.16
Book Value Growth (%)	13.69	13.47	144.31	0.33	94.96

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	27.91	89.54	51.69	0.00	62.97
Price / Book Value	3.61	3.87	10.14	2.24	15.26
Dividend Yield (%)	0.29	0.00	0.19	0.00	0.06
EV/EBITDA	17.07	27.45	31.05	19.72	79.31
Market Cap (₹ Cr)	3,933.72	19,071.62	12,753.19	18,108.89	19,988.69

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.31	0.43	0.21	0.68	0.01
Short term debt to equity ratio	0.09	0.09	0.05	0.09	0.01
Current Ratio	1.83	1.61	2.01	1.50	3.91
Quick Ratio	1.28	1.06	1.14	0.87	3.02
Interest Coverage	12.14	2.12	8.60	0.48	35.76

	Innova Captab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	26.83	17.43	29.00	24.33	28.85
Asset Turnover	0.96	0.49	2.01	0.64	0.76
Receivable days	84.59	58.75	40.13	78.20	90.06
Inventory Days	54.04	75.82	60.29	93.30	61.02
Payable days	114.83	186.21	232.47	226.14	96.06
Cash Conversion Cycle	23.80	-51.64	-132.04	-54.64	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.